Anavex Life Sciences Corp. (AVXL) stock
AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.72−0.02 (-2.78%)
Close on Nov 18, 2026Market cap $66.69MP/E –Yield –
Anavex Life Sciences total assets
Total assets on the balance sheet at the end of each period.
Anavex Life Sciences's total assets was $120.14M at Jun 30, 2026. For fiscal 2025 it was $103.82M, down 23.4% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $161.62M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $103.82M | -23.4% |
| FY2024 | Sep 30, 2024 | $135.57M | -12.2% |
| FY2023 | Sep 30, 2023 | $154.39M | +1.1% |
| FY2022 | Sep 30, 2022 | $152.71M | -5.5% |
| FY2021 | Sep 30, 2021 | $161.62M | +367.9% |
| FY2020 | Sep 30, 2020 | $34.54M | +36.4% |
| FY2019 | Sep 30, 2019 | $25.33M | -3.3% |
| FY2018 | Sep 30, 2018 | $26.21M | -5.9% |
| FY2017 | Sep 30, 2017 | $27.84M | +193.1% |
| FY2016 | Sep 30, 2016 | $9.50M | -38.6% |
| FY2015 | Sep 30, 2015 | $15.47M | +110.4% |
| FY2014 | Sep 30, 2014 | $7.35M | +1769.0% |
| FY2013 | Sep 30, 2013 | $393.45K | +2891.3% |
| FY2012 | Sep 30, 2012 | $13.15K | -93.5% |
| FY2011 | Sep 30, 2011 | $203.04K | -38.4% |
| FY2010 | Sep 30, 2010 | $329.85K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $120.14M | +17.3% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $128.77M | +9.9% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $132.99M | +7.2% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $103.82M | -23.4% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $102.43M | -27.6% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $117.14M | -18.9% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $124.04M | -16.2% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $135.57M | -12.2% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $141.54M | -10.3% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $144.52M | -9.2% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $148.07M | -0.2% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $154.39M | +1.1% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $157.81M | -1.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $159.19M | -0.7% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $148.37M | -5.4% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $152.71M | -5.5% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $160.22M | -3.7% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $160.28M | +91.8% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $156.90M | +188.8% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $161.62M | +367.9% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $166.42M | +426.1% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $83.57M | +169.4% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $54.33M | +72.9% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $34.54M | +36.4% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $31.63M | +44.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $31.02M | +51.0% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $31.42M | +42.2% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $25.33M | -3.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $21.97M | -18.0% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $20.55M | -20.6% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $22.10M | -22.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $26.21M | -5.9% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $26.79M | +7.6% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $25.90M | +9.7% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $28.34M | +32.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $27.84M | +193.1% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $24.91M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $23.61M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $21.37M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $9.50M | – |
See a number that looks wrong?